March 5, 2018 Life Science Tools

BD to Demonstrate Enhanced Integration Offerings that Target Key Gaps Across the Medication Management Process at HIMSS18

LAS VEGAS, March 5, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will demonstrate its comprehensive approach to integrated, enterprise medication management to help close the communication gaps across the medication management process through increased interoperability, enhanced cybersecurity and expanded partnerships at the 2018 HIMSS Annual Conference being... Read more

March 2, 2018 PR/Corporate

BD Announces Results of Offer to Repurchase its 3.000% Notes Due 2026

FRANKLIN LAKES, N.J., March 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the results of its previously announced offer to repurchase (the “Offer”) any and all of its outstanding 3.000% Notes due May 15, 2026 (the “Notes”) in accordance with the terms and conditions set forth in the offer to repurchase,... Read more

February 1, 2018 Licensing, IP, and Legal Product Launch

BD Launches New Los Angeles County Program to Equip Patients with Essential Resources for Safe Sharps Disposal

LOS ANGELES, Feb. 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new LA County program to help ensure proper containment and disposal of household sharps, a health concern that when disposed of improperly could cause injury or spread infection according to the U.S. Food... Read more

January 18, 2018 Uncategorized

BD Announces Completion of Enrollment in the Lutonix™ 014 Drug Coated Balloon Below-The-Knee Trial

FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, controlled trial intended... Read more

January 17, 2018 PR/Corporate Uncategorized

BD Announces Webcast of Annual Meeting of Shareholders

FRANKLIN LAKES, N.J., Jan. 17, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2018, at 1 p.m. (ET). The webcast can be accessed from the BD corporate website at http://www.bd.com/investors/ and... Read more

January 15, 2018 Uncategorized

BD and Check-Points Receive CE Mark for Next-generation Resistant Bacteria Screening Test

FRANKLIN LAKES, N.J., and WAGENINGEN, The Netherlands, Jan. 15, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. It... Read more

December 29, 2017 M&A, Partnerships

BD Completes Bard Acquisition, Creating New Global Health Care Leader

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. The combined company is uniquely positioned to... Read more

December 29, 2017 M&A, Partnerships PR/Corporate

BD Announces Expiration and Final Results of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the expiration and final results of its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C.... Read more

December 28, 2017 M&A, Partnerships PR/Corporate

BD Announces Extension of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C. R. Bard, Inc. (“Bard”) for new... Read more